TriangleAtovaquone (NCT05998135)
Atovaquone trial for Ovarian High Grade Serous Adenocarcinoma (NCT05998135). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult women with high-grade serous ovarian cancer that progressed within six months after their last platinum chemotherapy. There is no limit on earlier treatment lines.
The idea: repurpose oral atovaquone, an infection medicine, as a cancer treatment. Researchers test its proposed inhibition of STAT3 signaling and examine changes in tumor immune cells. Everyone receives atovaquone; there is no chemotherapy comparison arm. CT scans and biopsy or abdominal-fluid sampling track the study.
This phase 2 study plans 28 patients. Namita Khanna leads Emory's recruiting Atlanta site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.